A case of Stewart‑Treves syndrome occurring in the abdominal wall successfully treated with eribulin: A case report

Imura,Yoshinori; Nagata,Shigenori; Wakamatsu,Toru; Tanaka,Takaaki; Tamiya,Hironari; Naka,Norifumi; Takenaka,Satoshi

doi:10.3892/mco.2020.2119

A case of Stewart‑Treves syndrome occurring in the abdominal wall successfully treated with eribulin: A case report

Authors:
- Yoshinori Imura
- Shigenori Nagata
- Toru Wakamatsu
- Takaaki Tanaka
- Hironari Tamiya
- Norifumi Naka
- Satoshi Takenaka
View Affiliations

Affiliations: Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka 541‑8567, Japan, Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka 541‑8567, Japan
Published online on: August 20, 2020 https://doi.org/10.3892/mco.2020.2119
Article Number: 49
Copyright: © Imura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiosarcoma (AS) is a rare and aggressive tumor with high rates of local recurrence and distant metastasis. Stewart‑Treves syndrome (STS) is defined as AS arising in the setting of chronic lymphedema, and is extremely uncommon in the lower abdominal wall. Eribulin mesylate (eribulin) is a non‑taxane microtubule inhibitor that has been approved in Japan for treating soft tissue sarcoma. The current study reports the case of a 76 year‑old woman with STS in the lower abdominal wall who exhibited an excellent response to eribulin. Having undergone surgery and postoperative radiation therapy (RT) for cervical cancer 12 years earlier, the patient presented with a mass in her left lower abdominal wall, where chronic lymphedema had developed. Contrast‑enhanced computed tomography revealed multiple enhancing nodules in the left lower abdominal wall and edema of the subcutaneous tissues in the whole lower abdomen. A histologic analysis of the specimens revealed AS, and she was diagnosed as STS. A total of 3 cycles of combination chemotherapy with gemcitabine and docetaxel were administered, but the patient discontinued treatment owing to severe adverse events. RT was performed for the tumor, but multiple reddish nodules appeared in the whole lower abdominal wall 3 months later. At this point, eribulin administration was offered. After 4 cycles of treatment, there was a clear reduction in the size of the nodules. All lesions were stable, no new lesions had developed, and the side effects of treatment were minor over the course of 1 year. The results reveal that eribulin may serve as a potential therapeutic option for the treatment of STS.

View Figures

View References

1	Young RJ, Brown NJ, Reed MW, Hughes D and Woll PJ: Angiosarcoma. Lancet Oncol. 11:983–991. 2010.PubMed/NCBI View Article : Google Scholar
2	Stewart FW and Treves N: Lymphangiosarcoma in postmastectomy lymphedema; A report of six cases in elephantiasis chirurgica. Cancer. 1:64–81. 1948.PubMed/NCBI View Article : Google Scholar
3	McHaffie DR, Kozak KR, Warner TF, Cho CS, Heiner JP and Attia S: Stewart-treves syndrome of the lower extremity. J Clin Oncol. 28:e351–e352. 2010.PubMed/NCBI View Article : Google Scholar
4	Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, et al: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61:1013–1021. 2001.PubMed/NCBI
5	Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA and Wilson L: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 4:1086–1095. 2005.PubMed/NCBI View Article : Google Scholar
6	Okouneva T, Azarenko O, Wilson L, Littlefield BA and Jordan MA: Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 7:2003–2011. 2008.PubMed/NCBI View Article : Google Scholar
7	Sharma A and Schwartz RA: Stewart-treves syndrome: Pathogenesis and management. J Am Acad Dermatol. 67:1342–1348. 2012.PubMed/NCBI View Article : Google Scholar
8	Taswell HF, Soule EH and Coventry MB: Lymphangio-sarcoma arising in chronic lymphedematous extremities. Report of thirteen cases and review of literature. J Bone Joint Surg Am. 44-A:277–294. 1962.PubMed/NCBI
9	Grobmyer SR, Daly JM, Glotzbach RE and Grobmyer AJ III: Role of surgery in the management of postmastectomy extremity angiosarcoma (stewart-treves syndrome). J Surg Oncol. 73:182–188. 2000.PubMed/NCBI View Article : Google Scholar
10	Kerchner K, Fleischer A and Yosipovitch G: Lower extremity lymphedema update: Pathophysiology, diagnosis, and treatment guidelines. J Am Acad Dermatol. 59:324–331. 2008.PubMed/NCBI View Article : Google Scholar
11	Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, et al: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol. 15:415–423. 2014.PubMed/NCBI View Article : Google Scholar
12	Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK and Casper ES: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 86:2034–2037. 1999.PubMed/NCBI
13	Fury MG, Antonescu CR, Van Zee KJ, Brennan MF and Maki RG: A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 11:241–247. 2005.PubMed/NCBI View Article : Google Scholar
14	Skubitz KM and Haddad PA: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 104:361–366. 2005.PubMed/NCBI View Article : Google Scholar
15	Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M and Blay JY: Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 44:2433–2436. 2008.PubMed/NCBI View Article : Google Scholar
16	Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, et al: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: The ANGIOTAX study. J Clin Oncol. 26:5269–5274. 2008.PubMed/NCBI View Article : Google Scholar
17	Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T and Nishigori C: Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma: Report of 9 patients. Cancer. 110:648–651. 2007.PubMed/NCBI View Article : Google Scholar
18	Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, et al: Gemcitabine in advanced angiosarcoma: A retrospective case series analysis from the Italian rare cancer network. Ann Oncol. 23:501–508. 2012.PubMed/NCBI View Article : Google Scholar
19	Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K and Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 22:1706–1712. 2004.PubMed/NCBI View Article : Google Scholar
20	Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, et al: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet. 387:1629–1637. 2016.PubMed/NCBI View Article : Google Scholar
21	Demetri GD, Schoffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M and Chawla S: Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 35:3433–3439. 2017.PubMed/NCBI View Article : Google Scholar
22	Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, Morioka H, Matsumine A, Saito K, Asami S and Isu K: Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 47:137–144. 2017.PubMed/NCBI View Article : Google Scholar
23	Wada N, Uchi H and Furue M: Case of angiosarcoma of the scalp successfully controled by eribulin. J Dermatol. 45:116–117. 2018.PubMed/NCBI View Article : Google Scholar
24	Inagaki C, Shimoi T, Okuma H, Kitano A, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, et al: A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. Anticancer Drug. 29:97–101. 2018.PubMed/NCBI View Article : Google Scholar
25	Kobayashi E, Naito Y, Asano N, Maejima A, Endo M, Takahashi S, Megumi Y and Kawai A: Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol. 49:938–946. 2019.PubMed/NCBI View Article : Google Scholar
26	Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, Funakoshi T, Miyagi T, Hata H, Gosho M, et al: The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: A multicentre prospective observational study. Br J Dermatol 2020 (Epub ahead of print).